RT Book, Section A1 Damon, Lloyd E. A1 Andreadis, Charalambos Babis A2 Papadakis, Maxine A. A2 McPhee, Stephen J. A2 Rabow, Michael W. SR Print(0) ID 1175800568 T1 Chronic Myeloid Leukemia T2 Current Medical Diagnosis & Treatment 2021 YR 2021 FD 2021 PB McGraw-Hill Education PP New York, NY SN 9781260469868 LK accessmedicine.mhmedical.com/content.aspx?aid=1175800568 RD 2023/02/07 AB Key Clinical Updates in Chronic Myeloid LeukemiaIn patients with chronic myeloid leukemia who have not responded to treatment with multiple tyrosine kinase inhibitors, the novel allosteric inhibitor asciminib can be tried. It has shown a 54% complete hematologic response rate and a 48% sustained major molecular response in heavily pretreated patients.